Alzheimers

Healthcare

Biogen shares slip as Alzheimer's drug faces new setback

Shares of Biogen slipped nearly 4% in pre-market trading Wednesday after the biotech company's new Alzheimer's drug Aduhelm (aducanumab) received a "negative trend vote" from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP).